Author name: DrugPatentWatch

Every drug that reaches Phase III clinical trials carries two price tags: the cost of making it and the cost […]

Every year, generic drug manufacturers pay hundreds of millions of dollars in settlements and delayed-entry agreements that, in hindsight, were

By the time a patent cliff arrives, most pharmaceutical companies have already lost the war. The moment generic manufacturers file

Russia is a $9.2 billion pharmaceutical market where the rulebook on intellectual property is being rewritten in real time. [1]

Prosecute to Win: Why Your Drug Patent Portfolio Is Your Next Competitive Assertion Asset The moment a generic manufacturer files

Every year, brand-name pharmaceutical manufacturers watch billions of dollars in revenue disappear within weeks of a generic competitor hitting pharmacy

Every three years, a hospital’s pharmacy director sits across from a GPO account team and negotiates contracts that will govern

Every pharmaceutical patent filed with the FDA Orange Book names two things: who owns the invention, and who made it.

Most biotech executives say they allocate R&D capital rationally. Most are wrong. They favor programs with internal champions, compounds that